リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days

Sato, Yoshitaka Iguchi, Mitsutaka Kato, Yoshiaki Morioka, Hiroshi Hirabayashi, Aki Tetsuka, Nobuyuki Tomita, Yuka Kato, Daizo Yamada, Kiyofumi Kimura, Hiroshi Yagi, Tetsuya 名古屋大学

2020.08

概要

Prolonged treatment with linezolid (LZD) is known to cause thrombocytopenia. However, some patients do not develop thrombocytopenia despite long-term administration of LZD. To determine the risk factors for LZD-associated thrombocytopenia in patients undergoing long-term LZD therapy, we conducted a retrospective cohort study among 212 patients receiving LZD treatment between December 2011 and June 2014 at a tertiary referral university hospital in Nagoya, Japan. Of the 217 patients who received LZD, 37 were treated with LZD for more than 14 days and were enrolled in the study. We compared data on demographic characteristics, underlying disease, microbiology, concomitant drugs, and laboratory tests between the thrombocytopenia group and the non-thrombocytopenia group. Thrombocytopenia was defined as having a platelet count < 100 × 103/μL or a ≥ 50% reduction in platelet count compared to baseline. Among the 37 patients who received LZD for more than 14 days, 17 (45.9%) developed thrombocytopenia. Multivariate logistic regression revealed that both the number of concomitant drugs with thrombocytopenic adverse effects (DTADE) (OR = 1.690; 95% CI = 1.037–2.754; P = 0.035) and a small decrease in the level of C-reactive protein (CRP) 14 days post-administration (OR = 0.965; 95% CI = 0.939–0.993; P = 0.013) were associated with thrombocytopenia during long-term LZD therapy. Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy. Our findings may be useful for preventing thrombocytopenia in patients treated with LZD for longer than 14 days.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135–142.

2. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients

with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345–351.

3. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia

among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72.

4. Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolidinduced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795–799.

5. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin

Infect Dis. 2002;34(5):695–698.

6. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285(10):1291.

7. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of

adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy

in complex patients. Antimicrob Agents Chemother. 2006;50(4):1599–1602.

8. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and

vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect

Dis. 2004;38(8):1058–1064.

9. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience.

Antimicrob Agents Chemother. 2002;46(8):2723–2726.

10. Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid

and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother.

2011;55(5):1867–1873.

11. Cossu AP, Musu M, Mura P, De Giudici LM, Finco G. Linezolid-induced thrombocytopenia in impaired

renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin

Pharmacol. 2014;70(1):23–28.

12. Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, rifampin, and

renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother.

2007;51(7):2559–2563.

13. Grau S, Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Alvarez-Lerma F. Linezolid: low

pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother.

2005;56(2):440–441.

14. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in

adult patients. Infection. 2014;42(6):1007–1012.

15. Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with

the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.

Clin Ther. 2009;31(10):2126–2133.

16. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may

improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother.

2012;67(8):2034–2042.

17. Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW. Clarithromycin

significantly increases linezolid serum concentrations. Antimicrob Agents Chemother. 2010;54(12):5418–5419.

18. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric

analysis. Antimicrob Agents Chemother. 2010;54(11):4605–4610.

19. Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical

central nervous system infections. Antimicrob Agents Chemother. 2002;46(3):936–937.

20. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma

of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50(1):73–77.

21. Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using

3 distinct methods. Blood. 2010;116(12):2127–2133.

22. Waldrep TW, Skiest DJ. Linezolid-Induced anemia and thrombocytopenia. Pharmacotherapy. 2002;22(1):109–

112.

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る